Immunic THERAPEUTICS Immunic Therapeutics Fourth Quarter and Year-End 2021 Financial Results and Corporate Update NASDAQ: IMUX | February 24, 2022 Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements regar ...

Immunic, Inc. (NASDAQ:IMUX) Q3 Results Earnings Conference Call November 4, 2021 8:00 AM ET Company Participants Jessica Breu - Head of IR & Communications Daniel Vitt - CEO, President & Director Glenn Whaley - VP of Finance and Principal Financial & Accounting Officer Andreas Muehler - Chief Medical Officer Patrick Walsh - Chief Business Officer Inderpal Singh - General Counsel Conference Call Participants Yasmeen Rahimi - Piper Sandler Gobind Singh - JMP Securities Michael Kratky - SVB Leerink Matthe ...

IMMUNIC THERAPEUTICS Immunic Therapeutics Developing Selective Oral Drugs in Immunology NASDAQ: IMUX | August 2021 Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements regarding management's intentions, pl ...

| --- | --- | --- | --- | |-------|-------|-------|-------| | | | | | | | | | | | | | | | Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements regarding management's intentions, plans, beliefs, expectation ...

IMMUNIC THERAPEUTICS Immunic Therapeutics Developing Selective Oral Drugs in Immunology NASDAQ: IMUX | March 2021 Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements regarding management's intentions, pla ...

IMMUNIC THERAPEUTICS Immunic Therapeutics Developing Selective Oral Drugs in Immunology NASDAQ: IMUX | October 2020 Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements regarding management's intentions, p ...

Immunic, Inc. (NASDAQ:IMUX) Q2 2020 Earnings Conference Call August 3, 2020 8:30 AM ET Company Participants Jessica Breu - Head of Investor Relations and Communications Dr. Daniel Vitt - CEO, President and Director Dr. Andreas Muehler - Chief Medical Officer Conference Call Participants Liana Moussatos - Wedbush Pacgrow Healthcare Matthew Kaplan - Ladenburg Thalmann & Co. Inc. George Farmer - BMO Capital Markets Corp Yasmeen Rahimi - Piper Sandler Raghuram Selvaraju - H.C. Wainwright & Co. Zegbeh Jallah - R ...

Immunic Therapeutics Developing Selective Oral Drugs in Immunology NASDAQ: IMUX | June 2020 Cautionary Note Regarding Forward-Looking Statements Certain statements contained in this presentation regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include statements regarding management's intentions, plans, bel ...

| --- | --- | |-------|---------------------------------------------------------------------| | | | | | | | | | | | | | | Immunic Therapeutics Developing Selective Oral Drugs in Immunology | | | NASDAQ: IMUX February 2020 | Cautionary Note Regarding Forward-Looking Statements • Certain statements contained in this presentation regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Privat ...

Immunic Therapeutics Developing Selective Oral Drugs in Immunology NASDAQ: IMUX Piper Jaffray 31st Annual Healthcare Conference December 5, 2019 Cautionary Note Regarding Forward-Looking Statements • Certain statements contained in this presentation regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, known as the PSLRA. These include s ...